New Drug Mavacamten Shows Potential for Reducing Heart Stress in HFpEF Patients
Mavacamten, originally for hypertrophic cardiomyopathy, shows promise in reducing heart stress for HFpEF patients by lowering key cardiac biomarkers. The EMBARK-HFpEF trial highlights potential symptom improvements and a favorable safety…
